Sanofi-Aventis Offer To Buy Genzyme Seen As Starting Point For Long Negotiation

French pharma's initial offer in the $67 to $70 per share range expected to rise, perhaps into the $80s.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet